RISS 검색 - 국내학술지논문

무료
기관 내 무료
유료

내보내기
내책장담기
한글로보기

정확도순

내림차순

내림차순

10개씩 출력

1
Lack of Association between Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphisms and Panic Disorder in Korean Population

SeWon Lim,HeonJeong Lee,MinSoo Lee,KangSeob Oh 대한신경정신의학회 2007 PSYCHIATRY INVESTIGATION Vol.4 No.1
- 원문보기
Objective-Several lines of evidence suggest that brain-derived neurotrophic factor (BDNF) plays a role in the pathophysiology of anxiety. We analyzed the association of the BDNF gene val66met polymorphism, in the coding region of exon XIIIA in chromosome 11q and panic disorder (PD). Methods-One hundred and six patients with PD and 160 control subjects were tested for the BDNF (val66met) polymorphism. A clinical interview and MINI international neuropsychiatric interview were conducted by trained psychiatrists to diagnose panic disorder according to DSMIV. Information about the symptomatic characteristics of panic disorder was also gathered by measuring various clinical scales (Hamilton anxiety rating scale, Beck anxiety inventory, Spielberg State-Trait Anxiety inventory and Anxiety sensitivity index). Results-There were no significant differences in the frequencies of the genotypes (χ2=4.16, df=2, p=0.13), alleles (χ2=0.79, df=1, p=0.37) or allele (Met) carriers (χ2=0.28, df=1, p=0.59) between the patients and controls. In addition, in comparing the severity of panic disorder with the genotypes of the BDNF gene, we could not find any significant differences between the genotypes. Conclusions-These results suggest that BDNF (val66met) polymorphisms do not play a major role in the susceptibility to or severity of panic disorder in our Korean population.
2
Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics

JungSun Lee,Seockhoon Chung,JoonNoh Lee,JunSoo Kwon,DoHoon Kim,ChulEung Kim,KangSeob Oh,YangWhan Jeon,MinSoo Lee,MyungHo Lim,HyeRyein Chang,ChangYoon Kim 대한신경정신의학회 2010 PSYCHIATRY INVESTIGATION Vol.7 No.3
- 원문보기 3
  ScienceON
  
  KCI
  
  스콜라
Objective-To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks). Methods-This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole group. The effectiveness analysis consisted of the comparison of the upper bound of the 95% confidence interval (CI) of the mean Clinical Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study. Results-At the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) scores. The study showed that the mean CGI-I score was 2.92 (95% CI: 2.72-3.12) in the aripiprazole group and 2.81 (95% CI: 2.35-3.26) in the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8% and 72.6%, respectively, and 80.2% of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, and nausea. Conclusion-This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.